Verici Dx plc (VRCDF)
| Market Cap | 7.72M -27.7% |
| Revenue (ttm) | 3.66M +9.7% |
| Net Income | -6.93M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0030 |
| Previous Close | 0.0030 |
| Day's Range | 0.0030 - 0.0030 |
| 52-Week Range | 0.0030 - 2.9100 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 15, 2026 |
About Verici Dx
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and... [Read more]
Financial Performance
In 2025, Verici Dx's revenue was $3.66 million, an increase of 9.73% compared to the previous year's $3.34 million. Losses were -$6.93 million, 18.0% more than in 2024.
Financial StatementsNews
Verici Dx Earnings Call Transcript: H2 2025
RNA-based transplant tests achieved 32% Q1 revenue growth, with 29 U.S. centers now ordering and strong Medicare coverage. Recent equity raises extend cash runway, while a clear path to profitability is set at GBP 60 million annual sales.
Verici Dx Annual report: H2 2025
Verici Dx has published its H2 2025 annual report on July 8, 2026.
Verici Dx Annual report: H2 2025
Verici Dx has published its H2 2025 annual report on July 8, 2026.
Verici Dx Slides: H2 2025
Verici Dx has posted slides in relation to its H2 2025 quarterly earnings report, which was published on July 8, 2026.
Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from t...
Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that collaborators will present new data on the predictive ...
CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
FRANKLIN, Tenn.--(BUSINESS WIRE)--In the first and last paragraphs, the text should read: Pre-Transplant Risk Assessment (instead of: Pre-Transplant Rejection Assessment). The updated release reads: V...
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation s...
Verici Dx Earnings release: Q1 2026
Verici Dx released its Q1 2026 earnings on April 16, 2026, summarizing the period's financial results.
Verici Dx Earnings release: H2 2025
Verici Dx released its H2 2025 earnings on February 5, 2026, summarizing the period's financial results.
Verici Dx Earnings Call Transcript: H1 2025
Medicare coverage for Tutivia and a successful GBP 6.3 million fundraise enabled commercial expansion, with revenues recognized and a strong cash runway. Growth is expected from new center onboarding and an expanded sales team, with 2025 revenue targets maintained.
Verici Dx Quarterly report: H1 2025
Verici Dx has published its H1 2025 quarterly earnings report on October 7, 2025.
Verici Dx Slides: H1 2025
Verici Dx has posted slides in relation to its H1 2025 quarterly earnings report, which was published on October 7, 2025.
FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians
CORALVILLE, Iowa--(BUSINESS WIRE)--FBB Biomed today announced it has signed a Master Services Agreement with Verici Dx plc (AIM: VRCI.L), for Laboratory Services for Research-Use-Only (RUO) (FDA defin...